New diagnostic strategy for sepsis-induced disseminated intravascular coagulation: A prospective single-center observational study

Critical Care

Volumn 18, Issue 1, 2014, Pages

  Ishikura, Hiroyasu ^a   Nishida, Takeshi ^a   Murai, Akira ^a   Nakamura, Yoshihiko ^a   Irie, Yuhei ^a   Tanaka, Junichi ^a   Umemura, Takehiro ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; D DIMER; INTERLEUKIN 6; PRESEPSIN; PROCALCITONIN; PROTEIN; PROTEIN C; THROMBOMODULIN; UNCLASSIFIED DRUG; CD14 ANTIGEN; PEPTIDE FRAGMENT; PRESEPSIN PROTEIN, HUMAN;

ADULT; APACHE; ARTICLE; BLOOD SAMPLING; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; EMERGENCY PATIENT; EMERGENCY WARD; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTHROMBIN TIME; SEPSIS; SEPSIS INDUCED DISSEMINATED INTRAVASCULAR COAGULATION; SEPTIC SHOCK; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THROMBOCYTE COUNT; YOUNG ADULT; AGED; BLOOD; COMPLICATION; DISSEMINATED INTRAVASCULAR COAGULATION; METABOLISM; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD14; BIOLOGICAL MARKERS; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; PROTEIN C; SEPSIS; YOUNG ADULT;

EID: 84896708548     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc13700     Document Type: Article

References (51)

1. Moore LJ, Moore FA, Todd SR, Jones SL, Turner KL, Bass BL. Sepsis in general surgery: the 2005-2007 national surgical quality improvement program perspective. Arch Surg 2010, 145:695-700. 10.1001/archsurg.2010.107, 20644134.
2. Remick DG. Pathophysiology of sepsis. Am J Pathol 2007, 170:1435-1444. 10.2353/ajpath.2007.060872, 1854939, 17456750.
3. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb SA, Beale RJ, Vincent JL, Moreno R. Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2012. Crit Care Med 2013, 41:580-637. 10.1097/CCM.0b013e31827e83af, 23353941.
4. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992, 20:864-874. 10.1097/00003246-199206000-00025, 1597042.
5. Ogura H, Gando S, Iba T, Eguchi Y, Ohtomo Y, Okamoto K, Koseki K, Mayumi T, Murata A, Ikeda T, Ishikura H, Ueyama M, Kushimoto S, Saitoh D, Endo S, Shimazaki S. SIRS-associated coagulopathy and organ dysfunction in critically ill patients with thrombocytopenia. Shock 2007, 28:411-417. 10.1097/shk.0b013e31804f7844, 17577138.
6. Gando S, Kameue T, Nanzaki S, Nakanishi Y. Disseminated intravascular coagulation is a frequent complication of systemic inflammatory response syndrome. Thromb Haemost 1996, 75:224-228.
7. Range-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995, 273:117-123. 10.1001/jama.1995.03520260039030, 7799491.
8. Dhainaut JF, Yan SB, Joyce DE, Pettilä V, Basson B, Brandt JT, Sundin DP, Levi M. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2004, 2:1924-1933. 10.1111/j.1538-7836.2004.00955.x, 15550023.
9. Kienast J, Juers M, Wiedermann CJ, Hoffmann JN, Ostermann H, Strauss R, Keinecke HO, Warren BL, Opal SM. Treatments effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 2006, 4:90-97.
10. Beale R, Reinhart K, Brunkhorst FM, Dobb G, Levy M, Martin G, Martin C, Ramsey G, Silva E, Vallet B, Vincent JL, Janes JM, Sarwat S, Williams MD. Promoting Global Research Excellence in Severe Sepsis (PROGRESS): lessons from an international sepsis registry. Infection 2009, 37:222-232. 10.1007/s15010-008-8203-z, 19404580.
11. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008, 36:296-327. 10.1097/01.CCM.0000298158.12101.41, 18158437.
12. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R, Carlet J, Le Gall JR, Payen D. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006, 34:344-353. 10.1097/01.CCM.0000194725.48928.3A, 16424713.
13. Wittebole X, Castanares-Zapatero D, Laterre PF. Toll-like receptor 4 modulation as a strategy to treat sepsis. Mediators Inflamm 2010, 2010:568396. 2855078, 20396414.
14. Gando S, Iba T, Eguchi Y, Ohtomo Y, Okamoto K, Koseki K, Mayumi T, Murata A, Ikeda T, Ishikura H, Ueyama M, Ogura H, Kushimoto S, Saitoh D, Endo S, Shimazaki S. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med 2006, 34:625-631.
15. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985, 13:818-829. 10.1097/00003246-198510000-00009, 3928249.
16. Vincent JL, de Mendonça A, Cantraine F, Moreno R, Takala J, Suter PM, Sprung CL, Colardyn F, Blecher S. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on " sepsis-related problems" of the European Society of Intensive Care Medicine. Crit Care Med 1998, 26:1793-1800. 10.1097/00003246-199811000-00016, 9824069.
17. Kurihara T, Yanagida A, Yokoi H, Koyata A, Matsuya T, Ogawa J, Okamura Y, Miyamoto D. Evaluation of cardiac assays on a benchtop chemiluminescent enzyme immunoassay analyzer, PATHFAST. Anal Biochem 2008, 375:144-146. 10.1016/j.ab.2007.12.030, 18211813.
18. Okamura Y, Yokoi H. Development of a point-of-care assay system for measurement of presepsin (sCD14-ST). Clin Chim Acta 2011, 412:2157-2161. 10.1016/j.cca.2011.07.024, 21839732.
19. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982, 143:29-36.
20. Ulloa L, Tracey KJ. The " cytokine profile" : a code for sepsis. Trends Mol Med 2005, 11:56-63. 10.1016/j.molmed.2004.12.007, 15694867.
21. Padkin A, Goldfrad C, Brady AR, Young D, Black N, Rowan K. Epidemiology of severe sepsis occurring in the first 24 hrs in the intensive care unit in England, Wales, and Northern Ireland. Crit Care Med 2003, 31:2332-2338. 10.1097/01.CCM.0000085141.75513.2B, 14501964.
22. Peters K, Unger RE, Brunner J, Kirkpatrick CJ. Molecular basis of endothelial dysfunction in sepsis. Cardiovasc Res 2003, 60:49-57. 10.1016/S0008-6363(03)00397-3, 14522406.
23. van der Poll T, Levi M. Crosstalk between inflammation and coagulation: the lessons of sepsis. Curr Vasc Pharmacol 2012, 10:632-638. 10.2174/157016112801784549, 22272914.
24. Cohen J. The immunopathogenesis of sepsis. Nature 2002, 420:885-891. 10.1038/nature01326, 12490963.
25. Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med 2010, 38:S26-S34.
26. Zeerleder S, Hack CE, Wuillemin WA. Disseminated intravascular coagulation in sepsis. Chest 2005, 128:2864-2875. 10.1378/chest.128.4.2864, 16236964.
27. Wada H, Wakita Y, Nakase T, Shimura M, Hiyoyama K, Nagaya S, Mori Y, Shiku H. Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Mie DIC Study Group. Thromb Haemost 1995, 74:848-852.
28. Furusako S, Shirakawa K. Methods for detecting human low molecular weight CD14. 2008, US7465547 B2. United States patent.
29. Furusako S, Shirakawa K, Hirose J. Soluble CD14 antigen. 2009, US7608684 B2. United States patent.
30. Yaegashi Y, Shirakawa K, Sato N, Suzuki Y, Kojika M, Imai S, Takahashi G, Miyata M, Furusako S, Endo S. Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis. J Infect Chemother 2005, 11:234-238. 10.1007/s10156-005-0400-4, 16258819.
31. Kojika M, Takahashi G, Matsumoto N, Kikkawa T, Hoshikawa K, Shioya N, Shibata S, Suzuki Y, Aoki H, Shirakawa K, Endo S. Serum levels of soluble CD14 subtype reflect the APACHE II and SOFA Scores. Med Postgrad 2010, 48:46-50.
32. Takahashi G, Suzuki Y, Kojika M, Matsumoto N, Shozushima T, Makabe H, Yamada Y, Shioya N, Shibata S, Shirakawa K, Endo S. Evaluation of responses to IVIG therapy in patients with severe sepsis and septic shock by soluble CD14 subtype monitoring. Med Postgrad 2010, 48:19-24.
33. Shozushima T, Takahashi G, Matsumoto N, Kojika M, Okamura Y, Endo S. Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. J Infect Chemother 2011, 17:764-769. 10.1007/s10156-011-0254-x, 21560033.
34. Mussap M, Noto A, Fravega M, Fanos V. Soluble CD14 subtype presepsin (sCD14-ST) and lipopolysaccharide binding protein (LBP) in neonatal sepsis: new clinical and analytical perspectives for two old biomarkers. J Matern Fetal Neonatal Med 2011, 24:12-14.
35. Endo S, Suzuki Y, Takahashi G, Shozushima T, Ishikura H, Murai A, Nishida T, Irie Y, Miura M, Iguchi H, Fukui Y, Tanaka K, Nojima T, Okamura Y. Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study. J Infect Chemother 2012, 18:891-897. 10.1007/s10156-012-0435-2, 22692596.
36. Levi M, van der Poll T, ten Cate H, van Deventer SJ. The cytokine-mediated between coagulant and anticoagulant mechanisms in sepsis and endotoxemia. Eur J Clin Ivest 1997, 27:3-9.
37. Farthmann EH, Schoffel U. Principles and limitations of operative management of intaabdominal infections. World J Surg 1990, 14:210-217. 10.1007/BF01664875, 2183484.
38. Garcia-Sabrido JM, Talado JM, Christou NV. Treatment of severe inta-abdominal sepsis and/or necrotic foci by an open abdomen approach: zipper and zipper-mesh techniques. Arch Surg 1988, 123:152-156. 10.1001/archsurg.1988.01400260032002, 3277582.
39. Bernard GR, Hartman DL, Helterbrand JD, Fisher CJ. Recombinant human activated protein C (rhAPC) produces a trend toward improvement in morbidity and 28-day survival in patients with severe sepsis. Crit Care Med 1999, 27:S33-S35.
40. Bernard GR, Macias WL, Joyce DE, Williams MD, Bailey J, Vincent JL. Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis. Crit Care 2003, 7:155-163. 10.1186/cc2167, 270661, 12720562.
41. Yan SB, Dhainaut JF. Activated protein C versus protein C in severe sepsis. Crit Care Med 2001, 29:S69-S74.
42. Dhainaut JF, Yan SB, Cariou A, Mira JP. Soluble thrombomodulin, plasma-derived unactivated protein C, and recombinant human activated protein C in sepsis. Crit Care Med 2002, 30:S318-S323. 10.1097/00003246-200205001-00023, 12004254.
43. Bernard GR, Vincent JL, Laterre PF. Efficiacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709. 10.1056/NEJM200103083441001, 11236773.
44. Mesters RM, Helterbrand J, Utterback BG, Yan B, Chao YB, Fernandez JA, Griffin JH, Hartman DL. Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications. Crit Care Med 2000, 28:2209-2216.
45. Marlar RA, Endres BJ, Miler C. Serial studies of protein C and its plasma inhibitor in patients with DIC. Blood 1985, 66:59-63.
46. Jonge E, Levi M, Van der Poll T. Natural anticoagulants in disseminated intravascular coagulation and sepsis. Yearbook of Intensive Care and Emergency Medicine 2001, 348-352. Berlin: Springer-Verlag, Vincent JL.
47. Macias WL, Nelson DR. Severe protein C deficiency predicts early death in severe sepsis. Crit Care Med 2004, 32:S223-S228. 10.1097/01.CCM.0000126120.49367.AC, 15118522.
48. Fisher CJ, Yan SB. Protein C levels as a prognostic indicator of outcome in sepsis and related diseases. Crit Care Med 2000, 28:S49-S56. 10.1097/00003246-200009001-00011, 11007198.
49. Macias WL, Derchak PA. Coagulopathy may occur before the clinical diagnosis of organ dysfunction. Crit Care Med 2002, 30:S100.
50. Gando S, Saitoh D, Ogura H, Mayumi T, Koseki K, Ikeda T, Ishikura H, Iba T, Ueyama M, Eguchi Y, Ohtomo Y, Okamoto K, Kushimoto S, Endo S, Shimazaki S. Natural history of disseminated intravascular coagulation diagnosed based on the newly established diagnostic criteria for critically ill patients: results of a multicenter, prospective survey. Crit Care Med 2008, 36:145-150. 10.1097/01.CCM.0000295317.97245.2D, 18090367.
51. Taylor FB, Toh CH, Hoot WK, Wada H, Levi M. Toward definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001, 86:1327-1330.